Journal
GENE THERAPY
Volume 11, Issue 10, Pages 805-810Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.gt.3302233
Keywords
gene therapy; adeno-associated virus
Categories
Funding
- NCRR NIH HHS [RR 16586] Funding Source: Medline
- NEI NIH HHS [EY 13729] Funding Source: Medline
- NHLBI NIH HHS [HL 51811., HL 59412, HL 69877] Funding Source: Medline
- NIDDK NIH HHS [DK 58327] Funding Source: Medline
Ask authors/readers for more resources
Progress Many new AAV serotypes have been discovered Structural biology of AAV opens the door to new vector designs Receptor-targeted capsid mutants and alternative serotypes broaden the host range for rAAV-mediated gene transfer Postentry limitations to rAAV-mediated gene transfer have been identified, including proteasome-mediated vector degradation and limitations on transcriptional activation New data on the mechanisms of rAAV persistence help define potential risks and benefits of rAAV-mediated transduction Progress in rAAV production technology makes new applications feasible Clinical trials utilizing rAAV are expanded Barriers to rAAV-mediated gene transfer in the clinical setting are identified Barriers to repeated dosing of rAAV Prospects Use of small molecules to overcome intracellular barriers to rAAV transduction Clinical applications based on achieving sustained secretion of extracellular transgene products Gene modification approaches to regenerative medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available